Insulin glargine and lixisenatide Subcutaneous and MPI DTPA
Determining the interaction of Insulin glargine and lixisenatide Subcutaneous and MPI DTPA and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: insulin glargine / lixisenatide
Brand name: Soliqua 100/33
Synonyms: Insulin glargine and lixisenatide (Subcutaneous)
Generic Name: pentetate calcium trisodium
Brand name:
Synonyms: Pentetate, Pentetate Calcium Trisodium
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Insulin glargine and lixisenatide Subcutaneous-MS Contin
- Insulin glargine and lixisenatide Subcutaneous-MST
- Insulin glargine and lixisenatide Subcutaneous-MTX Support
- Insulin glargine and lixisenatide Subcutaneous-MucaphEd
- Insulin glargine and lixisenatide Subcutaneous-Mucinex Allergy
- Insulin glargine and lixisenatide Subcutaneous-Mucinex Cough Mini-Melts
- MPI DTPA-Insulin glargine, recombinant Subcutaneous
- MPI DTPA-Insulin glulisine
- MPI DTPA-Insulin Glulisine (Cartridges and Pens)
- MPI DTPA-Insulin Glulisine (Vials)
- MPI DTPA-Insulin glulisine Subcutaneous
- MPI DTPA-Insulin human inhaled Inhalation